Class: Use (276)
Method of using exendin and GLP-1 to affect the central nervous system
Patent Number: 5846937This patent may be interesting for Amylin from San Diego to look at. Why it is interesting is because, I believe, Amylin actually has taken some of the compounds described in this patent to the clinic. This patent teaches the use of GLP-1 and/or exendin-4 for modulation of central nervous system activity.
System for the in vivo delivery and expression of heterologous genes in the bone marrow
Patent Number: 6583121Gene therapy would greatly benefit from the ability to use stem cells as vectors. This patent addresses the problem of transfecting stem cells through the use of alpha viruses. Some clinical trials are already underway using alpha viruses.
Methods for promoting healing of skin resurfacing wounds
Patent Number: 6713084This patent covers methods of healing skin after a laser wound through the application of stem cells, or various epithelial cells that may be either allogeneic or xenogeneic.
Cloning pigs using non-quiescent differentiated donor cells or nuclei
Patent Number: 7,291,764Cloning and genetic manipulation of pigs is desirable not only for research uses but also for potential pharmaceuticals (ie generation of proteins in transgenic pig seminal fluid) as well as xenotransplantation of genetically modified pig organs into humans. Unfortunately cloning of pigs is more difficult than cloning of other species. In this patent methods of cloning pigs are provided...
Biomaterial derived from vertebrate liver tissue
Patent Number: 6793939This patent covers the use of liver tissue derived basement membrane material for the stimulation of endogenous or exogenous stem cells. One interesting use of this patent would be the combination of cord blood stem cells with liver tissue extract for stimulation of various regenerative applications.
Biomaterial derived from vertebrate liver tissue
Patent Number: 6379710This patent teaches that one can take an organ from an allogeneic or xenogeneic animal, decellularize the organ, and use the matrix components of the organ as a scaffold to be seeded with stem cells either in vitro or in vivo, and used for the generation of a new organ. In one specific embodiment, livers are generated using this approach.
Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
Patent Number: 6544787This patent provides methods of performing hematopoietic transplants without having to wipe out the recipient's myelopoietic system. Specifically the patent teaches ways of inducing tolerance. This can be used not only for stem cell transplants, but also to induce donor-specific tolerance in a variety of solid organ transplant settings.
Gene therapy methods using bone marrow-derived cells expressing blood clotting factors
Patent Number: 6410015This patent covers hematopoietic stem cells that are gene transfected with various clotting factors. In some embodiments the stem cells have a preferntially affinity towards injured tissue.
Factor IX delivery method using bone marrow-derived cells
Patent Number: 6277369This patent teaches how to transfect hematopoietic stem cells with various genes, including the gene for Factor IX. Transfection is performed by first treating the stem cells with TGF beta in order to increase rate of DNA incorporation.
Pharmaceutical products comprising endothelial cell precursors
Patent Number: 6569428This patent provides the endothelial stem cell together with endothelial stem cell activatory genes as a pharmaceutical preparation for the stimulation of angiogenesis. This patent is useful for the treatment of ischemic disorders ranging from angina, to cerebral palsy, to peripheral vascular disease.